Immunotherapy Toxicities.
Immune checkpoint inhibitors side effects
Immune-related adverse events (irAE)
Mechanisms of irAE
T cell mediated toxicity
Journal
Surgical oncology clinics of North America
ISSN: 1558-5042
Titre abrégé: Surg Oncol Clin N Am
Pays: United States
ID NLM: 9211789
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
entrez:
14
5
2019
pubmed:
14
5
2019
medline:
6
5
2020
Statut:
ppublish
Résumé
Immune checkpoint inhibitors (ICIs) are therapeutic antibodies that target regulatory molecules on T cells and represent the most widely used FDA-approved class of immunotherapy. ICIs are associated with unique immune-mediated toxicities called immune-related adverse events. These toxicities may affect any organ system, and their precise mechanisms of action remain under investigation. Current evidence suggests that activation of T cells is involved, although other components of the immune response have been implicated. This article summarizes toxicities, potential mechanisms of action, management strategies, and other clinical considerations. Unique mechanisms of action and immune-related toxicities of other FDA-approved classes of immunotherapy are reviewed.
Identifiants
pubmed: 31079795
pii: S1055-3207(19)30023-7
doi: 10.1016/j.soc.2019.02.009
pii:
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
387-401Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.